Bioactive Metabolomic Profiles of Scleroderma-PAH are different than idiopathic PAH and associated with worse clinical outcomes

Abstract The molecular signature in patients with systemic sclerosis (SSc)-associated pulmonary arterial hypertension (SSc-PAH) relative to idiopathic pulmonary arterial hypertension (IPAH) remain unclear. We hypothesize that patients with SSc-PAH exhibit unfavorable bioactive metabolite derangements compared to IPAH that contribute to their poor prognosis and limited response to therapy. We sought to determine whether circulating bioactive metabolites are differentially altered in SSc-PAH versus IPAH. Plasma biosamples from 415 patients with SSc-PAH (cases) and 1115 patients with IPAH (controls) were included in the study. Over 700 bioactive metabolites were assayed in plasma samples from independent discovery and validation cohorts using liquid chromatography - mass spectrometry (LC-MS) based approaches. Regression analyses were used to identify metabolites which exhibited differential levels between SSc-PAH and IPAH and associated with disease severity. From among hundreds of circulating bioactive molecules, twelve metabolites were found to distinguish between SSc-PAH and IPAH, as well as associate with PAH disease severity. SSc-PAH patients had increased levels of fatty acid metabolites including lignoceric acid and nervonic acid, as well as kynurenine, polyamines, eicosanoids/oxylipins and sex hormone metabolites relative to IPAH. In conclusion, SSc-PAH patients are characterized by an unfavorable bioactive metabolic profile that may explain the poor and limited response to therapy. These data provide important metabolic insights into the pathogenesis of SSc-PAH. Take Home Message Among patients with PAH, those with SSc-PAH suffer disproportionately worse outcomes and disease course. This study represents the most comprehensive analysis of bioactive metabolites profiling comparing two subgroups of PAH. The findings shed light on key differences between SSc-PAH and IPAH that provide important metabolic insight into the disease pathogenesis.